...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Clinical Pharmacology: Official Journal of the American College of Clinical Pharmacology >Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.
【24h】

Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorpan HBr.

机译：利奈唑胺：与伪麻黄碱HCl，苯丙醇胺HCl和右美沙芬HBr共同给药的药代动力学和药效学评价。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Linezolid is a novel oxazolidinone antibiotic with mild reversible monoamine oxidase inhibitor (MAOI) activity. The potential for interaction with over-the-counter (OTC) medications requires quantification. The authors present data evaluating the pharmacokinetic and pharmacodynamic responses to coadministration of oral linezolid with sympathomimetics (pseudoephedrine and phenylpropanolamine) and a serotonin reuptake inhibitor (dextromethorphan). Following coadministration with linezolid, minimal but statistically significant increases were observed in pseudoephedrine and phenylpropanolamine plasma concentrations; a minimal but statistically significant decrease was observed in dextrorphan (the primary metabolite of dextromethorphan) plasma concentrations. Increased blood pressure (BP) was observed following the coadministration of linezolid with either pseudoephedrine or phenylpropanolamine; no significant effects were observed with dextromethorphan. None of these coadministered drugs had a significant effect on linezolid pharmacokinetics. Minimal numbers of adverse events were reported. Potentiation of sympathomimetic activity by linezolid was judged not to be clinically significant, but patients sensitive to the effects of increased BP due to predisposing factors should be treated cautiously. No restrictions are indicated for the coadministration of dextromethorphan and linezolid.
机译：利奈唑胺是一种新型的恶唑烷酮抗生素，具有中等程度的可逆单胺氧化酶抑制剂（MAOI）活性。与非处方（OTC）药物相互作用的潜力需要量化。作者介绍了评估口服利奈唑胺与拟交感神经药（伪麻黄碱和苯丙醇胺）和5-羟色胺再摄取抑制剂（右美沙芬）共同给药对药代动力学和药效学反应的数据。与利奈唑胺合用后，伪麻黄碱和苯丙醇胺血浆中的浓度增至最小，但在统计学上显着增加。观察到右啡烷（右美沙芬的主要代谢产物）血浆浓度有最小但统计学上显着的降低。利奈唑胺与伪麻黄碱或苯丙醇胺并用后，血压升高。右美沙芬未观察到明显的作用。这些共同给药的药物均未对利奈唑胺的药代动力学产生重大影响。据报道不良事件最少。利奈唑胺对拟交感神经药活性的增强作用在临床上不被认为是重要的，但是对因诱发因素而导致血压升高的敏感性敏感的患者应谨慎治疗。对于右美沙芬和利奈唑胺的共同给药没有限制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号